Business · 16/05/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to X4 Pharmaceuticals for Rare Pediatric Disease Product XOLREMDI
Summary
The FDA has awarded a priority review voucher to X4 Pharmaceuticals, Inc. for its rare pediatric disease product XOLREMDI (mavorixafor), approved on April 26, 2024, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →